Daridorexant (ACT-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder in the elderly: results from a randomized, double-blind, placebo-controlled, 5-period, 5-treatment crossover dose-response phase 2 study

Autor:	Yves Dauvilliers, Gary Zammit, D. Sebök Kinter, Dieter Kunz, Scott Pain
Rok vydání:	2019
Předmět:	business.industry Period (gene) Crossover Antagonist Phases of clinical research General Medicine Placebo Orexin receptor Double blind Anesthesia Insomnia medicine medicine.symptom business
Zdroj:	Sleep Medicine. 64:S437-S438
ISSN:	1389-9457
DOI:	10.1016/j.sleep.2019.11.1228
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8c226bebafba87e13213b71495daf68a https://doi.org/10.1016/j.sleep.2019.11.1228 Zobrazit plný text záznamu Full Text from ScienceDirect